C5 and paroxysmal nocturnal hemoglobinuria: The value in deciphering the intricacies of this web of molecular and cellular relationships on disease outcome, is underlined by the overwhelming success of the terminal pathway anti-C5 antibodies, eculizumab and ravulizumab, in preventing the devastating thrombotic manifestations of aHUS and PNH (13, 14, 193).